TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kymera Therapeutics (KYMR – Research Report), Nektar Therapeutics (NKTR – Rese ...

Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Investing.com - BofA Securities raised its price target on Kymera Therapeutics (NASDAQ: KYMR) to $54.00 from $51.00 on Thursday, while maintaining a Buy rating on the stock following several pipeline ...